ELAVL1 and Patent ductus arteriosus: Nevertheless, despite the acknowledged limitations in their study, Tatarian et al. provided enough evidence to support the notion that cHuR may be predictive of 5-FU efficacy in patients with resectable PDA and high cHuR, thereby challenging previous studies that highlight HuR as promoter of chemotherapy resistance [32,41,42].